Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies

Andrew P. Stein(University of Wisconsin–Madison), Randall J. Kimple(University of Wisconsin–Madison)

Cancer Medicine

January 26, 2015

10.1002/cam4.387

Cited by 23

Related Papers

Postacute COVID‐19 Laryngeal Injury and Dysfunction

|OTO Open|2021|48

Discordant <scp>SARS‐CoV</scp>‐2 Detection in the Nasopharynx Versus Trachea for Patients With Tracheostomies

|The Laryngoscope|2021|4

Evaluation of MMR Concordance Based on Either International Scale (IS) or National Comprehensive Cancer Network (NCCN) Criteria Using Reconstructed “Virtual” CML Patient Profiles From the REVEAL BCR-ABL Methods Comparison Study,

|Blood|2011|0

Posterior glottic stenosis following prolonged intubation for COVID-19

|Journal of Head & Neck Anesthesia|2021|0

Abstract 5060: Role of molecular driver mutations in recurrence of early stage laryngeal cancer following narrow field definitive radiotherapy

|Cancer Research|2024|0